Khodayar Oshvandi; Maryam Aghamohammadi; Farideh Kazemi; Seyedeh Zahra Masoumi; Mehrdokht Mazdeh; Mehdi Molavi Vardanjani
Volume 22, Issue 10 , 2020
Abstract
Background: Among the most important chronic diseases is multiple sclerosis (MS) leading to physical disability and decrease in the patients? quality of life.
Objectives: The present study aimed to investigate the effect of the royal jelly capsule on the life quality of patients with MS.
Methods: This ...
Read More
Background: Among the most important chronic diseases is multiple sclerosis (MS) leading to physical disability and decrease in the patients? quality of life.
Objectives: The present study aimed to investigate the effect of the royal jelly capsule on the life quality of patients with MS.
Methods: This randomized clinical trial study was conducted on a total of 100 patients referring to the MS Society of Hamadan, Iran, in 2018. Allocation sequences were determined using block randomization with a block size of 4, and the subjects were assigned to the intervention and control groups according to a predetermined sequence. The intervention group received one royal jelly capsule (500 mg) daily, and the control group received a placebo capsule for 90 days. The life quality of the patients and their daily activities were evaluated using the specific questionnaire for the life quality of the patients with MS and Barthel Index of Daily Living Activities before and after the intervention. Data analysis was performed by Stata software (version 13) and appropriate statistical tests with a significance level of 0.05.
Results: The comparison of the mean score of the patients? life quality showed that it was higher in the experimental group in the post-intervention (66.51±15.08) than that reported for the control group (51.31±15.08) after controlling possible confounding factors, which was statistically significant (P<0.001). Furthermore, Cohen's d (1.01; 95% CI: 0.59-1.42) also indicated the intended large effect size of the intervention. The comparison of daily activity status scores between the two groups also demonstrated an improvement in the experimental group (18.76±1.44), compared to that of the control group (16.96±3.01), which was statistically significant (P=0.001).
Conclusions: Based on the findings of the current study, it can be concluded that the use of the royal jelly supplement can be effective in the improvement of the life quality of the patients with MS.
Romina Dastmalchi; Mir Davood Omrani; Mehrdokht Mazdeh; Shahram Arsang-Jang; Abolfazl Movafagh; Arezou Sayad; Mohammad Taheri
Volume 20, Issue 8 , 2018, Pages 1-6
Abstract
Background: Multiple sclerosis (MS) is an autoimmune and multifactorial disease, and its pathogenesis is associated with many genetic and environmental factors. Long Non-coding RNA (lncRNAs) are a group of genes that have recently been identified as pre- disposing genetic factors for the development ...
Read More
Background: Multiple sclerosis (MS) is an autoimmune and multifactorial disease, and its pathogenesis is associated with many genetic and environmental factors. Long Non-coding RNA (lncRNAs) are a group of genes that have recently been identified as pre- disposing genetic factors for the development of many cancers. Objectives: This is a case–control study to evaluate the expression of two lncRNAs including Urothelial Carcinoma Associated 1 (UCA1) and Cancer-Associated Transcript 2 (CCAT2) in Relapsing-Remitting Multiple Sclerosis (RRMS) patients compared to healthy control group.Methods: In this case-control study, the expression of UCA1 and CCAT2 was evaluated in 50 RRMS patients (37 females, 13 males with a mean age of 36.2 ± 2.9 years) compared to 50 healthy controls (38 females, 12 males with a mean age of 35.3 ± 2.1), using the TaqMan real-time PCR technique. This study was conducted during 2017 and 2018 at Shahid Beheshti University of Medical Sciences, Tehran, Iran. Results: There was no significant difference between the overall expression of UCA1 (P = 0.282) and CCAT2 (P = 0.983) among the case and control groups. However, there was a significant difference in the expression of UCA1 in female patients older than 40 years incomparison with healthy age-matched females (P = 0.013). In addition, there was a significant correlation between the expression of UCA1 and CCAT2 (P < 0.0001). Conclusions: These results suggest the synergistic effects of UCA1 and CCAT2 on pathogenic aspects of MS, by affecting cellular signaling pathways such as WNT and NF-kB.
